A Blank Rome team successfully represented MH Parent, LLC in the sale of its subsidiary Millennium Health, LLC ("Millennium") to Laboratory Corporation of America Holdings (“Labcorp”). Labcorp announced the definitive agreement on October 23, 2026, and the transaction closed on November 3, 2026. The estimated purchase price for the transaction is up to $375m, including $245m payable in cash at closing and up to $130m of consideration contingent upon the outcome of specified future events.
Millennium is an accredited specialty laboratory with more than 15 years of experience in drug testing and surveillance. Its testing gives clinicians critical insight into patients' recent use of prescription medications and illicit drugs. Clinicians use those insights to monitor and treat people living with chronic pain, substance use disorders, mental health conditions, and other health needs. Through the acquisition, Labcorp aims to expand toxicology testing access nationwide. Millennium's patients, clinicians, and customers are expected to benefit from Labcorp's extensive test menu, its national network of patient service centers, and its digital tools for test ordering and result delivery.
“Blank Rome provided extraordinary service throughout this transaction. They guided us through a lengthy and highly complex negotiation with patience, skill, and sound judgment, and they helped us achieve a very favorable outcome. We’re grateful for their good counsel,” said Peter Sisitsky, Chairman of the Board, MH Parent, LLC.
For more information, please read: Labcorp Announces Definitive Agreement to Acquire Millennium Health (October 23, 2026).
The Blank Rome team was led by Robert P. Zinn and Megan A. Wotherspoon, and included Rachel C. Sanders, Daniel O'Connor, and Amanda Lin (CMAS); Andrew B. Pullman (Tax); Rachael G. Pontikes, Emily L. Hussey, Eric S. Tower, and Kelly J. Kearney (Healthcare); Stephen C. Zumbrun (Environmental); Michael A. Kadlec and Stephen M. Pennartz (Executive Compensation & Employee Benefits); and Jeremy A. Rist, Yelena M. Barychev, and Melissa A. Griest (Antitrust).